Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 18 de 18
Filter
Add more filters










Publication year range
1.
Cell Rep Med ; 4(5): 101036, 2023 05 16.
Article in English | MEDLINE | ID: mdl-37196635

ABSTRACT

Genetic and in vivo evidence suggests that aberrant recognition of RNA-containing autoantigens by Toll-like receptors (TLRs) 7 and 8 drives autoimmune diseases. Here we report on the preclinical characterization of MHV370, a selective oral TLR7/8 inhibitor. In vitro, MHV370 inhibits TLR7/8-dependent production of cytokines in human and mouse cells, notably interferon-α, a clinically validated driver of autoimmune diseases. Moreover, MHV370 abrogates B cell, plasmacytoid dendritic cell, monocyte, and neutrophil responses downstream of TLR7/8. In vivo, prophylactic or therapeutic administration of MHV370 blocks secretion of TLR7 responses, including cytokine secretion, B cell activation, and gene expression of, e.g., interferon-stimulated genes. In the NZB/W F1 mouse model of lupus, MHV370 halts disease. Unlike hydroxychloroquine, MHV370 potently blocks interferon responses triggered by specific immune complexes from systemic lupus erythematosus patient sera, suggesting differentiation from clinical standard of care. These data support advancement of MHV370 to an ongoing phase 2 clinical trial.


Subject(s)
Autoimmune Diseases , Lupus Erythematosus, Systemic , Humans , Mice , Animals , Toll-Like Receptor 7/metabolism , Toll-Like Receptor 7/therapeutic use , Lupus Erythematosus, Systemic/drug therapy , Lupus Erythematosus, Systemic/metabolism , Hydroxychloroquine/pharmacology , Hydroxychloroquine/therapeutic use , Interferons
2.
J Allergy Clin Immunol ; 140(6): 1632-1642, 2017 Dec.
Article in English | MEDLINE | ID: mdl-28412393

ABSTRACT

BACKGROUND: Eosinophils are a subset of granulocytes that can be involved in the pathogenesis of different diseases, including allergy. Their effector functions are closely linked to their cytotoxic granule proteins. Release takes place through several different mechanisms, one of which is cytolysis, which is associated with release of intact granules, so-called clusters of free eosinophil granules. The mechanism underlying this activation-induced form of cell death in eosinophils has remained unclear. OBJECTIVE: We aimed to elucidate the molecular mechanism of eosinophil cytolysis. METHODS: Isolated blood eosinophils were incubated on glass coverslips coated with intravenous immunoglobulin and inactive complement component 3b. A morphologic characterization of the distinct stages of the proposed cascade was addressed by means of time-lapse automated fluorescence microscopy, electron microscopy, and immunohistochemistry. Experiments with pharmacologic inhibitors were performed to elucidate the sequence of events within the cascade. Tissue samples of patients with eosinophilic skin diseases or eosinophilic esophagitis were used for in vivo analyses. RESULTS: After eosinophil adhesion, we observed reactive oxygen species production, early degranulation, and granule fusion processes, leading to a distinct morphology exhibiting cytoplasmic vacuolization and, finally, cytolysis. Using a pharmacologic approach, we demonstrate the presence of a receptor-interacting protein kinase 3 (RIPK3)-mixed lineage kinase-like (MLKL) signaling pathway in eosinophils, which, after its activation, leads to the production of high levels of reactive oxygen species in a p38 mitogen-activated protein kinase and phosphatidylinositol 3'-kinase-dependent manner. All these steps are required for cytoplasmic vacuolization and subsequent cytolysis to occur. Interestingly, triggering cytolysis is associated with an induction of autophagy in eosinophils, and additional stimulation of autophagy by means of pharmacologic inhibition of the mechanistic target of rapamycin counterregulates cell death. Moreover, MLKL phosphorylation, cytoplasmic vacuolization, and cytolysis were observed in eosinophils under in vivo inflammatory conditions. CONCLUSION: We report that adhesion-induced eosinophil cytolysis takes place through RIPK3-MLKL-dependent necroptosis, which can be counterregulated by autophagy.


Subject(s)
Eosinophilic Esophagitis/immunology , Eosinophils/immunology , Hypersensitivity/immunology , Protein Kinases/metabolism , Receptor-Interacting Protein Serine-Threonine Kinases/metabolism , Skin/immunology , Autophagy , Cell Adhesion , Cells, Cultured , Complement C3b/metabolism , Cytotoxicity, Immunologic , Humans , Immunoglobulins, Intravenous/metabolism , Molecular Targeted Therapy , Signal Transduction
3.
Cell Death Differ ; 23(12): 1961-1972, 2016 12.
Article in English | MEDLINE | ID: mdl-27740624

ABSTRACT

Eosinophils are frequently elevated in pathological conditions and can cause tissue damage and disease exacerbation. The number of eosinophils in the blood is largely regulated by factors controlling their production in the bone marrow. While several exogenous factors, such as interleukin-5, have been described to promote eosinophil differentiation, comparatively little is known about eosinophil-intrinsic factors that control their de novo generation. Here, we report that the small atypical GTPase RhoH is induced during human eosinophil differentiation, highly expressed in mature blood eosinophils and further upregulated in patients suffering from a hypereosinophilic syndrome. Overexpression of RhoH increases, in a Rho-associated protein kinase-dependent manner, the expression of GATA-2, a transcription factor involved in regulating eosinophil differentiation. In RhoH-/- mice, we observed reduced GATA-2 expression as well as accelerated eosinophil differentiation both in vitro and in vivo. Conversely, RhoH overexpression in bone marrow progenitors reduces eosinophil development in mixed bone marrow chimeras. These results highlight a novel negative regulatory role for RhoH in eosinophil differentiation, most likely in consequence of altered GATA-2 levels.


Subject(s)
Eosinophils/metabolism , Transcription Factors/metabolism , rho GTP-Binding Proteins/metabolism , Animals , Bone Marrow/metabolism , Cell Count , Cell Cycle , Cell Differentiation , Cell Movement , Cell Survival , Cells, Cultured , Chimera , Eosinophils/cytology , GATA2 Transcription Factor/metabolism , Humans , Immunophenotyping , Interleukin-5/metabolism , Longevity , Mice, Inbred C57BL , Mice, Knockout , Phenotype , Receptors, Interleukin-5/metabolism , Up-Regulation
4.
Mol Cell ; 57(6): 1011-1021, 2015 Mar 19.
Article in English | MEDLINE | ID: mdl-25728769

ABSTRACT

Eosinophils are white blood cells that function in innate immunity and participate in the pathogenesis of various inflammatory and neoplastic disorders. Their secretory granules contain four cytotoxic proteins, including the eosinophil major basic protein (MBP-1). How MBP-1 toxicity is controlled within the eosinophil itself and activated upon extracellular release is unknown. Here we show how intragranular MBP-1 nanocrystals restrain toxicity, enabling its safe storage, and characterize them with an X-ray-free electron laser. Following eosinophil activation, MBP-1 toxicity is triggered by granule acidification, followed by extracellular aggregation, which mediates the damage to pathogens and host cells. Larger non-toxic amyloid plaques are also present in tissues of eosinophilic patients in a feedback mechanism that likely limits tissue damage under pathological conditions of MBP-1 oversecretion. Our results suggest that MBP-1 aggregation is important for innate immunity and immunopathology mediated by eosinophils and clarify how its polymorphic self-association pathways regulate toxicity intra- and extracellularly.


Subject(s)
DNA-Binding Proteins/chemistry , DNA-Binding Proteins/metabolism , Eosinophils/metabolism , Animals , Cell Death/drug effects , Cell Line/drug effects , Cell Membrane/drug effects , Cellulitis/metabolism , Cellulitis/pathology , DNA-Binding Proteins/toxicity , Dermatitis, Atopic/metabolism , Dermatitis, Atopic/pathology , Eosinophilia/metabolism , Eosinophilia/pathology , Epithelial Cells/drug effects , Epithelial Cells/metabolism , Escherichia coli/drug effects , Host-Pathogen Interactions , Humans , Immunity, Innate/physiology , Mice, Inbred C57BL , Nanoparticles/metabolism , Nanoparticles/toxicity , Secretory Vesicles/metabolism , Skin/drug effects , Skin/pathology
5.
J Leukoc Biol ; 95(2): 293-303, 2014 Feb.
Article in English | MEDLINE | ID: mdl-24163421

ABSTRACT

The tight regulation of granulocyte chemotaxis is crucial for initiation and resolution of inflammation. Here, we show that DAPK2, a Ca(2+)/CaM-sensitive serine/threonine kinase known to modulate cell death in various cell types, is a novel regulator of migration in granulocytes. We demonstrate that human neutrophils and eosinophils express DAPK2 but unlike other leukocytes, no DAPK1 or DAPK3 protein. When DAPK activities were blocked by inhibitors, we found that neither granulocyte lifespan nor phagocytosis was affected. However, such pharmacological inactivation of DAPK activity abolished motility of granulocytes in response to intermediary but not end-target chemoattractants ex vivo. The defect in chemotaxis in DAPK2-inactive granulocytes is likely a result of reduced polarization of the cells, mediated by a lack of MLC phosphorylation, resulting in radial F-actin and pseudopod formation. As neutrophils treated with DAPKi also showed reduced recruitment to the site of inflammation in a mouse peritonitis model, DAPK2 may be a novel target for anti-inflammatory therapies.


Subject(s)
Cell Movement/drug effects , Chemotactic Factors/pharmacology , Death-Associated Protein Kinases/metabolism , Eosinophils/cytology , Neutrophils/cytology , Neutrophils/enzymology , Animals , Cell Adhesion/drug effects , Cell Polarity/drug effects , Cell Survival/drug effects , Death-Associated Protein Kinases/antagonists & inhibitors , Disease Models, Animal , Eosinophils/drug effects , Eosinophils/enzymology , Humans , Inflammation/pathology , Jurkat Cells , Mice , Myosin Light Chains/metabolism , Neutrophils/drug effects , Peritonitis/pathology , Phosphorylation , Protein Kinase Inhibitors/pharmacology , Small Molecule Libraries/pharmacology
6.
J Vis Exp ; (79): e50951, 2013 Sep 19.
Article in English | MEDLINE | ID: mdl-24084687

ABSTRACT

In this protocol we provide a method to isolate dendritic cells (DC) and epithelial cells (TEC) from the human thymus. DC and TEC are the major antigen presenting cell (APC) types found in a normal thymus and it is well established that they play distinct roles during thymic selection. These cells are localized in distinct microenvironments in the thymus and each APC type makes up only a minor population of cells. To further understand the biology of these cell types, characterization of these cell populations is highly desirable but due to their low frequency, isolation of any of these cell types requires an efficient and reproducible procedure. This protocol details a method to obtain cells suitable for characterization of diverse cellular properties. Thymic tissue is mechanically disrupted and after different steps of enzymatic digestion, the resulting cell suspension is enriched using a Percoll density centrifugation step. For isolation of myeloid DC (CD11c(+)), cells from the low-density fraction (LDF) are immunoselected by magnetic cell sorting. Enrichment of TEC populations (mTEC, cTEC) is achieved by depletion of hematopoietic (CD45(hi)) cells from the low-density Percoll cell fraction allowing their subsequent isolation via fluorescence activated cell sorting (FACS) using specific cell markers. The isolated cells can be used for different downstream applications.


Subject(s)
Cytological Techniques/methods , Dendritic Cells/cytology , Epithelial Cells/cytology , Immunomagnetic Separation/methods , Myeloid Cells/cytology , Thymus Gland/cytology , Centrifugation, Density Gradient/methods , Dendritic Cells/immunology , Epithelial Cells/immunology , Humans , Myeloid Cells/immunology , Thymus Gland/immunology
7.
Nat Commun ; 4: 2039, 2013.
Article in English | MEDLINE | ID: mdl-23783831

ABSTRACT

Ever since it was discovered that central tolerance to self is imposed on developing T cells in the thymus through their interaction with self-peptide major histocompatibility complexes on thymic antigen-presenting cells, immunologists have speculated about the nature of these peptides, particularly in humans. Here, to shed light on the so-far unknown human thymic peptide repertoire, we analyse peptides eluted from isolated thymic dendritic cells, dendritic cell-depleted antigen-presenting cells and whole thymus. Bioinformatic analysis of the 842 identified natural major histocompatibility complex I and II ligands reveals significant cross-talk between major histocompatibility complex-class I and II pathways and differences in source protein representation between individuals as well as different antigen-presenting cells. Furthermore, several autoimmune- and tumour-related peptides, from enolase and vimentin for example, are presented in the healthy thymus. 302 peptides are directly derived from negatively selecting dendritic cells, thus providing the first global view of the peptide matrix in the human thymus that imposes self-tolerance in vivo.


Subject(s)
Central Tolerance/immunology , Major Histocompatibility Complex/immunology , Peptides/immunology , Thymus Gland/immunology , Adolescent , Antigen Presentation/immunology , Antigen-Presenting Cells/immunology , Autoantigens/immunology , Autoimmunity/immunology , CD11c Antigen/metabolism , Child, Preschool , Dendritic Cells/cytology , Dendritic Cells/immunology , Epitopes/immunology , Female , Histocompatibility Antigens Class I/metabolism , Histocompatibility Antigens Class II/metabolism , Humans , Infant , Ligands , Male , Myeloid Cells/cytology , T-Lymphocytes/cytology , T-Lymphocytes/immunology , Thymus Gland/cytology
8.
Trends Immunol ; 34(8): 398-409, 2013 Aug.
Article in English | MEDLINE | ID: mdl-23665135

ABSTRACT

Neutrophils, eosinophils, and basophils play essential roles during microbe-induced and sterile inflammation. The severity of such inflammatory processes is controlled, at least in part, by factors that regulate cell death and survival of granulocytes. In recent years, major progress has been made in understanding the molecular mechanisms of granulocyte cell death and in identifying novel damage- and pathogen-associated molecular patterns as well as regulatory cytokines impacting granulocyte viability. Furthermore, an increased interest in innate immunity has boosted our overall understanding of granulocyte biology. In this review, we describe and compare factors and mechanisms regulating neutrophil, eosinophil, and basophil lifespan. Because dysregulation of death pathways in granulocytes can contribute to inflammation-associated immunopathology, targeting granulocyte lifespan could be therapeutically promising.


Subject(s)
Basophils/cytology , Eosinophils/cytology , Inflammation/immunology , Neutrophils/cytology , Animals , Basophils/immunology , Cell Death/immunology , Eosinophils/immunology , Humans , Neutrophils/immunology
9.
J Autoimmun ; 38(4): 332-43, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22424724

ABSTRACT

The interaction of developing thymocytes with peptide-MHC complexes on thymic antigen presenting cells (APC) is crucial for T cell development, both for positive selection of "useful" thymocytes as well as negative selection of autoreactive thymocytes to prevent autoimmunity. The peptides presented on MHC II molecules are generated by lysosomal proteases such as the cathepsins. At the same time, lysosomal proteases will also destroy other potential T cell epitopes from self-antigens. This will lead to a lack of presentation on negatively selecting thymic antigen presenting cells and consequently, escape of autoreactive T cells recognizing these epitopes. In order to understand the processes that govern generation or destruction of self-epitopes in thymic APC, we studied the antigen processing machinery and epitope processing in the human thymus. We find that each type of thymic APC expresses a different signature of lysosomal proteases, providing indirect evidence that positive and negative selection of CD4(+) T cells might occur on different sets of peptides, in analogy to what has been proposed for CD8(+) T cells. We also find that myeloid dendritic cells (DC) are more efficient in processing autoantigen than plasmacytoid DC. In addition, we observed that cathepsin S plays a central role in processing of the autoantigens myelin basic protein and proinsulin in thymic dendritic cells. Cathepsin S destroyed a number of known T cell epitopes, which would be expected to result in lack of presentation and consequently, escape of autoreactive T cells. Cathepsin S therefore appears to be an important factor that influences selection of autoreactive T cells.


Subject(s)
Antigen Presentation/immunology , Autoantigens/immunology , Cathepsins/metabolism , Dendritic Cells/immunology , Thymus Gland/immunology , Amino Acid Sequence , Autoantigens/metabolism , Dendritic Cells/metabolism , Humans , Molecular Sequence Data , Myelin Basic Protein/immunology , Myelin Basic Protein/metabolism , Proinsulin/immunology , Proinsulin/metabolism , Thymus Gland/metabolism
10.
Lung Cancer ; 76(3): 493-5, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22420949

ABSTRACT

In contrast to leukocytosis, paraneoplastic hypereosinophilia is uncommon in lung cancer. We present a patient with large-cell carcinoma of the lung, in which cancer cells generate large amounts of GM-CSF leading to a leukemoid reaction with prominent hypereosinophilia and potentially involved in autocrine tumor stimulation.


Subject(s)
Carcinoma, Large Cell/complications , Carcinoma, Large Cell/metabolism , Eosinophilia/etiology , Granulocyte Colony-Stimulating Factor/blood , Lung Neoplasms/complications , Lung Neoplasms/metabolism , Carcinoma, Large Cell/drug therapy , Eosinophilia/diagnosis , Fatal Outcome , Humans , Lung Neoplasms/drug therapy , Male , Middle Aged
11.
J Immunol Methods ; 373(1-2): 209-18, 2011 Oct 28.
Article in English | MEDLINE | ID: mdl-21925181

ABSTRACT

Neutrophils are terminally differentiated cells with a short life-span due to constitutive apoptosis. Because of these characteristics, genetic manipulation of neutrophils has been difficult, although it is highly desired given the importance of neutrophils in the immune system. Here we demonstrate that transduction of primary human mature neutrophils with enhanced green fluorescent protein (eGFP)-encoding lentiviral particles results in GFP-containing cells as previously reported. Yet, our data further show that GFP expression in neutrophils upon transduction is largely due to protein transfer, a process called lentiviral pseudotransduction, and not due to bona fide transduction. Thus, inhibition of viral genome integration by the reverse transcriptase inhibitor 3'-azido-3'-deoxythymidine (AZT) or of protein biosynthesis by cycloheximide (CHX) did not abolish GFP levels in transduced neutrophils. Importantly, lentiviral pseudotransduction of the enzyme death-associated protein kinase 2 (DAPK2) into primary human mature neutrophils resulted in increased protein levels, but not enzymatic functionality. Based on our data and previous reports of unspecific viral effects on immune cells following lentiviral transduction, we discourage scientists to use lentiviral transduction methods to manipulate primary mature neutrophils.


Subject(s)
Lentivirus/genetics , Neutrophils/metabolism , Recombinant Fusion Proteins/metabolism , Transduction, Genetic/methods , Apoptosis Regulatory Proteins/genetics , Apoptosis Regulatory Proteins/metabolism , Calcium-Calmodulin-Dependent Protein Kinases/genetics , Calcium-Calmodulin-Dependent Protein Kinases/metabolism , Cells, Cultured , Cycloheximide/pharmacology , Death-Associated Protein Kinases , Flow Cytometry , Genetic Vectors/genetics , Green Fluorescent Proteins/genetics , Green Fluorescent Proteins/metabolism , Humans , Immunoblotting , Jurkat Cells , Mutation , Neutrophils/cytology , Neutrophils/drug effects , Phosphorylation , Protein Synthesis Inhibitors/pharmacology , Recombinant Fusion Proteins/genetics , Reverse Transcriptase Inhibitors/pharmacology , Reverse Transcriptase Polymerase Chain Reaction , Transcription, Genetic/genetics , Zidovudine/pharmacology
12.
Biochimie ; 92(11): 1674-80, 2010 Nov.
Article in English | MEDLINE | ID: mdl-20347002

ABSTRACT

A genetic deficiency of the cysteine protease cathepsin L (Ctsl) in mice results in impaired positive selection of conventional CD4+ T helper cells as a result of an incomplete processing of the MHC class II associated invariant chain or incomplete proteolytic generation of positively selecting peptide ligands. The human genome encodes, in contrast to the mouse genome, for two cathepsin L proteases, namely cathepsin L (CTSL) and cathepsin V (CTSV; alternatively cathepsin L2). In the human thymic cortex, CTSV is the predominately expressed protease as compared to CTSL or other cysteine cathepsins. In order to analyze the functions of CTSL and CTSV in the positive selection of CD4+ T cells we employed Ctsl knock-out mice crossed either with transgenic mice expressing CTSL under the control of its genuine human promoter or with transgenic mice expressing CTSV under the control of the keratin 14 (K14) promoter, which drives expression to the cortical epithelium. Both human proteases are expressed in the thymus of the transgenic mice, and independent expression of both CTSL and CTSV rescues the reduced frequency of CD4+ T cells in Ctsl-deficient mice. Moreover, the expression of the human cathepsins does not change the number of CD4+CD25+Foxp3+ regulatory T cells, but the normalization of the frequency of conventional CD4+ T cell in the transgenic mice results in a rebalancing of conventional T cells and regulatory T cells. We conclude that the functional differences of CTSL and CTSV in vivo are not mainly determined by their inherent biochemical properties, but rather by their tissue specific expression pattern.


Subject(s)
Cathepsin L/deficiency , Cathepsin L/genetics , Cathepsins/genetics , Cysteine Endopeptidases/genetics , Gene Knockout Techniques , T-Lymphocytes, Helper-Inducer/metabolism , Thymus Gland/cytology , Thymus Gland/metabolism , Animals , CD4 Antigens/metabolism , Cathepsin L/metabolism , Cathepsins/metabolism , Cysteine Endopeptidases/metabolism , Forkhead Transcription Factors/metabolism , Gene Expression , HLA-D Antigens/metabolism , Haplotypes , Humans , Interleukin-2 Receptor alpha Subunit/metabolism , Mice , T-Lymphocytes, Regulatory/metabolism , Transgenes/genetics
13.
Results Probl Cell Differ ; 51: 149-72, 2010.
Article in English | MEDLINE | ID: mdl-19582405

ABSTRACT

CD4(+) T cells play a central role in the pathogenesis of multiple sclerosis (MS). Generation, activation and effector function of these cells crucially depends on their interaction with MHC II-peptide complexes displayed by antigen presenting cells (APC). Processing and presentation of self antigens by different APC therefore influences the disease course at all stages. Selection by thymic APC leads to the generation of autoreactive T cells, which can be activated by peripheral APC. Reactivation by central nervous system APC leads to the initiation of the inflammatory response resulting in demyelination. In this review we will focus on how MHC class II antigenic epitopes are created by different APC from the thymus, the periphery and from the brain, and will discuss the relevance of the balance between creation and destruction of such epitopes in the context of MS. A solid understanding of these processes offers the possibility for designing future therapeutic strategies.


Subject(s)
Antigen Presentation/immunology , Multiple Sclerosis/immunology , Animals , Autoantigens/immunology , Brain/immunology , Encephalomyelitis, Autoimmune, Experimental/immunology , Epitopes, T-Lymphocyte/biosynthesis , Histocompatibility Antigens Class II/immunology , Humans , Mice , Myelin Basic Protein , Myelin Proteins , Myelin Proteolipid Protein/immunology , Myelin-Associated Glycoprotein/immunology , Myelin-Oligodendrocyte Glycoprotein , Nerve Tissue Proteins/immunology , Protein Processing, Post-Translational/immunology , Thymus Gland/immunology , Transcription Factors/immunology
14.
J Immunol ; 183(2): 841-8, 2009 Jul 15.
Article in English | MEDLINE | ID: mdl-19542375

ABSTRACT

FOXP3-expressing naturally occurring CD4(+)CD25(high) T regulatory cells (Treg) are relevant in the control of autoimmunity, and a defect in this cell population has been observed in several human autoimmune diseases. We hypothesized that altered functions of peripheral Treg cells might play a role in the immunopathogenesis of myasthenia gravis, a T cell-dependent autoimmune disease characterized by the presence of pathogenic autoantibodies specific for the nicotinic acetylcholine receptor. We report in this study a significant decrease in the in vitro suppressive function of peripheral Treg cells isolated from myasthenia patients in comparison to those from healthy donors. Interestingly, Treg cells from prednisolone-treated myasthenia gravis patients showed an improved suppressive function compared with untreated patients, suggesting that prednisolone may play a role in the control of the peripheral regulatory network. Indeed, prednisolone treatment prevents LPS-induced maturation of monocyte-derived dendritic cells by hampering the up-regulation of costimulatory molecules and by limiting secretion of IL-12 and IL-23, and enhancing IL-10. In addition, CD4(+) T cells cultured in the presence of such tolerogenic dendritic cells are hyporesponsive and can suppress autologous CD4(+) T cell proliferation. The results shown in this study indicate that prednisolone treatment promotes an environment that favors immune regulation rather than inflammation.


Subject(s)
Dendritic Cells/immunology , Immune Tolerance/drug effects , Myasthenia Gravis/drug therapy , Prednisolone/pharmacology , T-Lymphocytes, Regulatory/immunology , Adult , Aged , Aged, 80 and over , Autoimmunity/drug effects , Case-Control Studies , Cell Proliferation , Coculture Techniques , Humans , Interleukins/metabolism , Lipopolysaccharides , Middle Aged , Myasthenia Gravis/immunology , Prednisolone/therapeutic use
15.
Exp Hematol ; 37(2): 266-75, 2009 Feb.
Article in English | MEDLINE | ID: mdl-19100676

ABSTRACT

OBJECTIVE: Cathepsin W (CatW, lymphopain) is a putative cysteine protease with restricted expression to natural killer (NK) cells and CD8(+) T cells and so far unknown function and properties. Here, we characterize in detail, the regulation of human CatW during T-cell development in response to different stimuli and its functional involvement in cytotoxic lymphocyte effector function. MATERIALS AND METHODS: Western blots and real time polymerase chain reaction of sorted, unstimulated, and stimulated cell subsets (thymocytes, T cells, NK cells) and their culture supernatants were used to study regulation and expression of CatW. Primary CD8(+) T cells and short-term T-cell lines were transfected with small interfering RNA to study the involvement of CatW in effector function such as target cell killing and interferon-gamma production. RESULTS: Levels of CatW expression correlate closely with cytotoxic capacity both during development and in response to factors influencing cytotoxicity. Furthermore, CatW is secreted during specific target cell killing. However, knockdown of CatW expression by small interfering RNA neither influences target cell killing nor interferon-gamma production. CONCLUSION: Despite being expressed in the effector subset of CD8(+) and NK cells and of being released during target cell killing, our functional inhibition studies exclude an essential role of CatW in the process of cytotoxicity.


Subject(s)
CD8-Positive T-Lymphocytes/immunology , Cathepsins/immunology , Cysteine Endopeptidases/immunology , Gene Expression Regulation, Enzymologic/immunology , Killer Cells, Natural/immunology , CD8-Positive T-Lymphocytes/enzymology , Cathepsin W , Cathepsins/antagonists & inhibitors , Cathepsins/biosynthesis , Cells, Cultured , Cysteine Endopeptidases/biosynthesis , Humans , Immunity, Cellular/physiology , Interferon-gamma/biosynthesis , Interferon-gamma/immunology , Killer Cells, Natural/enzymology , RNA, Small Interfering/immunology
16.
Cell Immunol ; 255(1-2): 41-5, 2009.
Article in English | MEDLINE | ID: mdl-19036358

ABSTRACT

Cathepsins are required for the processing of antigens in order to make them suitable for loading on major histocompatibility complex (MHC) class II molecules, for subsequent presentation to CD4(+) T cells. It was shown that antigen processing in monocyte-derived dendritic cells (DC), a commonly used DC model, is different from that of primary human DC. Here, we report that the two subsets of human myeloid DC (mDC) and plasmacytoid DC (pDC) differ in their cathepsin distribution. The serine protease cathepsin G (CatG) was detected in mDC1, mDC2, pDC, cortical thymic epithelial cells (cTEC) and high levels of CatG were determined in pDC. To address the role of CatG in the processing and presentation of a Multiple Sclerosis-associated autoantigen myelin basic protein (MBP), we used a non-CatG expressing fibroblast cell line and fibroblasts, which were preloaded with purified CatG. We find that preloading fibroblasts with CatG results in a decrease of MBP84-98-specific T cell proliferation, when compared to control cells. Our data suggest a different processing signature in primary human antigen-presenting cells and CatG may be of functional importance.


Subject(s)
Antigen-Presenting Cells/immunology , Cathepsins/immunology , Serine Endopeptidases/immunology , Antigen Presentation/immunology , Antigen-Presenting Cells/classification , Antigen-Presenting Cells/cytology , Antigen-Presenting Cells/enzymology , Aspartic Acid Endopeptidases/metabolism , Autoantigens/metabolism , Cathepsin G , Cell Line , Cysteine Endopeptidases/metabolism , Humans , Male , Multiple Sclerosis/immunology , Myelin Basic Protein/metabolism
18.
J Neuroimmunol ; 201-202: 41-9, 2008 Sep 15.
Article in English | MEDLINE | ID: mdl-18649950

ABSTRACT

CD4(+) T cells specific for the acetylcholine receptor (AChR) are assumed to play an important role in pathogenesis of myasthenia gravis (MG). A large and diverse number of potential T cell epitopes have been reported for different experimental setups aiming at the identification of disease-relevant T cells in MG. Investigating the T cell response to the epsilon subunit of human AChR, we explore complementary in vitro and in vivo approaches (PBMC from MG patients and mice transgenic for HLA-DR3 and human CD4) to address the possibilities and limitations of different strategies for elucidating natural autoimmune T cell epitopes.


Subject(s)
Epitope Mapping , Epitopes/physiology , Myasthenia Gravis/pathology , Receptors, Nicotinic/chemistry , T-Lymphocytes, Helper-Inducer/immunology , Amino Acid Sequence , Animals , Apolipoprotein B-100/pharmacology , CD4 Antigens/genetics , Dose-Response Relationship, Drug , HLA-DR3 Antigen/genetics , Humans , Mice , Mice, Transgenic , Myasthenia Gravis/blood , Peptide Fragments/immunology , Protein Binding/drug effects , Receptors, Nicotinic/immunology , Receptors, Nicotinic/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...